Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage i non-small-cell lung cancer

Wen Pin Chien, Ruey Hong Wong, Tsu Chin Wu, Ya Wen Cheng, Chih Yi Chen, Huei Lee

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Accumulated evidence suggests that p53 function altered by its gene mutation or genetic polymorphism contributes to tumor malignancy. Association of p53 mutation and its codon 72 polymorphism with lung cancer prognosis has been extensively studied. However, the joint effect of p53 mutation and p53 codon 72 polymorphism on lung cancer prognosis remains uncertain. Methods: In the present study, 266 primary lung cancer patients were included and overall survival was calculated. Genomic DNA prepared from adjacent normal lung and lung tumor tissues was used to determine p53 codon 72 genotype and p53 mutation by polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) and direct sequencing, respectively. Results: For all stages, neither p53 codon 72 genotype nor p53 mutation is associated with lung cancer prognosis. However, stage I patients with p53 mutation had a 1.79-fold hazard ratio [95% confidence interval (CI) 1.04-3.10] for overall survival when compared with p53 wild-type patients. Notably, stage I patients with p53 mutation and p53 codon 72 Pro/Pro genotype experienced a 2.66-fold hazard ratio (95% CI 1.21-5.85) for overall survival when compared with those with p53 wild-type and Arg/Arg genotype. An increased prognostic value was not observed in stage I patients with p53 wild-type and p53 Pro72 allele or in those with p53 mutation and p53 codon 72 Arg/Arg genotype. Conclusions: We therefore suggest that p53 codon 72 Pro allele potentially increases the prognostic value of p53 mutation in stage I non-small-cell lung cancer.

Original languageEnglish
Pages (from-to)1918-1924
Number of pages7
JournalAnnals of Surgical Oncology
Volume16
Issue number7
DOIs
Publication statusPublished - Jul 2009
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Codon
Alleles
Mutation
Genotype
Lung Neoplasms
Survival
Confidence Intervals
Neoplasms
Lung
Genetic Polymorphisms
Restriction Fragment Length Polymorphisms
Polymerase Chain Reaction
DNA
Genes

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage i non-small-cell lung cancer. / Chien, Wen Pin; Wong, Ruey Hong; Wu, Tsu Chin; Cheng, Ya Wen; Chen, Chih Yi; Lee, Huei.

In: Annals of Surgical Oncology, Vol. 16, No. 7, 07.2009, p. 1918-1924.

Research output: Contribution to journalArticle

Chien, Wen Pin ; Wong, Ruey Hong ; Wu, Tsu Chin ; Cheng, Ya Wen ; Chen, Chih Yi ; Lee, Huei. / Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage i non-small-cell lung cancer. In: Annals of Surgical Oncology. 2009 ; Vol. 16, No. 7. pp. 1918-1924.
@article{4a7bceaca09c4f0c801ae4e71a4f9879,
title = "Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage i non-small-cell lung cancer",
abstract = "Background: Accumulated evidence suggests that p53 function altered by its gene mutation or genetic polymorphism contributes to tumor malignancy. Association of p53 mutation and its codon 72 polymorphism with lung cancer prognosis has been extensively studied. However, the joint effect of p53 mutation and p53 codon 72 polymorphism on lung cancer prognosis remains uncertain. Methods: In the present study, 266 primary lung cancer patients were included and overall survival was calculated. Genomic DNA prepared from adjacent normal lung and lung tumor tissues was used to determine p53 codon 72 genotype and p53 mutation by polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) and direct sequencing, respectively. Results: For all stages, neither p53 codon 72 genotype nor p53 mutation is associated with lung cancer prognosis. However, stage I patients with p53 mutation had a 1.79-fold hazard ratio [95{\%} confidence interval (CI) 1.04-3.10] for overall survival when compared with p53 wild-type patients. Notably, stage I patients with p53 mutation and p53 codon 72 Pro/Pro genotype experienced a 2.66-fold hazard ratio (95{\%} CI 1.21-5.85) for overall survival when compared with those with p53 wild-type and Arg/Arg genotype. An increased prognostic value was not observed in stage I patients with p53 wild-type and p53 Pro72 allele or in those with p53 mutation and p53 codon 72 Arg/Arg genotype. Conclusions: We therefore suggest that p53 codon 72 Pro allele potentially increases the prognostic value of p53 mutation in stage I non-small-cell lung cancer.",
author = "Chien, {Wen Pin} and Wong, {Ruey Hong} and Wu, {Tsu Chin} and Cheng, {Ya Wen} and Chen, {Chih Yi} and Huei Lee",
year = "2009",
month = "7",
doi = "10.1245/s10434-009-0495-4",
language = "English",
volume = "16",
pages = "1918--1924",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage i non-small-cell lung cancer

AU - Chien, Wen Pin

AU - Wong, Ruey Hong

AU - Wu, Tsu Chin

AU - Cheng, Ya Wen

AU - Chen, Chih Yi

AU - Lee, Huei

PY - 2009/7

Y1 - 2009/7

N2 - Background: Accumulated evidence suggests that p53 function altered by its gene mutation or genetic polymorphism contributes to tumor malignancy. Association of p53 mutation and its codon 72 polymorphism with lung cancer prognosis has been extensively studied. However, the joint effect of p53 mutation and p53 codon 72 polymorphism on lung cancer prognosis remains uncertain. Methods: In the present study, 266 primary lung cancer patients were included and overall survival was calculated. Genomic DNA prepared from adjacent normal lung and lung tumor tissues was used to determine p53 codon 72 genotype and p53 mutation by polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) and direct sequencing, respectively. Results: For all stages, neither p53 codon 72 genotype nor p53 mutation is associated with lung cancer prognosis. However, stage I patients with p53 mutation had a 1.79-fold hazard ratio [95% confidence interval (CI) 1.04-3.10] for overall survival when compared with p53 wild-type patients. Notably, stage I patients with p53 mutation and p53 codon 72 Pro/Pro genotype experienced a 2.66-fold hazard ratio (95% CI 1.21-5.85) for overall survival when compared with those with p53 wild-type and Arg/Arg genotype. An increased prognostic value was not observed in stage I patients with p53 wild-type and p53 Pro72 allele or in those with p53 mutation and p53 codon 72 Arg/Arg genotype. Conclusions: We therefore suggest that p53 codon 72 Pro allele potentially increases the prognostic value of p53 mutation in stage I non-small-cell lung cancer.

AB - Background: Accumulated evidence suggests that p53 function altered by its gene mutation or genetic polymorphism contributes to tumor malignancy. Association of p53 mutation and its codon 72 polymorphism with lung cancer prognosis has been extensively studied. However, the joint effect of p53 mutation and p53 codon 72 polymorphism on lung cancer prognosis remains uncertain. Methods: In the present study, 266 primary lung cancer patients were included and overall survival was calculated. Genomic DNA prepared from adjacent normal lung and lung tumor tissues was used to determine p53 codon 72 genotype and p53 mutation by polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) and direct sequencing, respectively. Results: For all stages, neither p53 codon 72 genotype nor p53 mutation is associated with lung cancer prognosis. However, stage I patients with p53 mutation had a 1.79-fold hazard ratio [95% confidence interval (CI) 1.04-3.10] for overall survival when compared with p53 wild-type patients. Notably, stage I patients with p53 mutation and p53 codon 72 Pro/Pro genotype experienced a 2.66-fold hazard ratio (95% CI 1.21-5.85) for overall survival when compared with those with p53 wild-type and Arg/Arg genotype. An increased prognostic value was not observed in stage I patients with p53 wild-type and p53 Pro72 allele or in those with p53 mutation and p53 codon 72 Arg/Arg genotype. Conclusions: We therefore suggest that p53 codon 72 Pro allele potentially increases the prognostic value of p53 mutation in stage I non-small-cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=67649185268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649185268&partnerID=8YFLogxK

U2 - 10.1245/s10434-009-0495-4

DO - 10.1245/s10434-009-0495-4

M3 - Article

C2 - 19434453

AN - SCOPUS:67649185268

VL - 16

SP - 1918

EP - 1924

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 7

ER -